NCT01031212View on ClinicalTrials.gov

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2013

Conditions
Tumors
Interventions
DRUG

ASA404

Administered intravenously over 20 minutes weekly after chemotherapy

DRUG

Cetuximab

Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter

DRUG

Carboplatin

Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle

DRUG

Paclitaxel

Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle

Trial Locations (1)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of California, San Francisco

OTHER